Recent FDA committee vote could speed multiple myeloma drug approval
MIAMI, FLORIDA (May 21, 2024) – A U.S. Food and Drug Administration committee voted unanimously in April to approve a new clinical endpoint, minimal residual disease (MRD), when evaluating proposed drugs to treat multiple myeloma. Credit: Photo by Sylvester MIAMI, FLORIDA (May 21, 2024) –